Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1128/mBio.00473-21 http://scihub22266oqcxt.onion/10.1128/mBio.00473-21 34281392!8406180!34281392     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       mBio 2021 ; 12 (4): e0047321 Nephropedia Template TP {{tp|p=34281392|t=2021. Tackling Antimicrobial Resistance in the Shadow of COVID-19 |pdf=|usr=}}{{34281392}} gab.com Text Tackling Antimicrobial Resistance in the Shadow of COVID-19 JO: mBio http://www.kidney.de/pget.php?&tw=1&pmid=34281392 #FOAvip The coronavirus disease 2019 (COVID-19) pandemic is a challenge for ongoing efforts to combat antimicrobial-resistant (AMR) bacterial infections. As we learn more about COVID-19 disease and drug stewardship evolves, there is likely to be a lasting impact of increased use of antimicrobial agents and antibiotics, as well as a lack of consistent access to health care across many populations. Sexually transmitted infections have been underreported during the pandemic and are often caused by some of the most drug-resistant pathogens. In their recent article in mBio, Parzych et al. (E. M. Parzych, S. Gulati, B. Zheng, M. A. Bah, et al., mBio 12:e00242-21, 2021, https://doi.org/10.1128/mBio.00242-21) focus on protection against Neisseria gonorrhoeae infection via in vivo delivery of an antigonococcal DNA-encoded antibody that has been modified for increased complement activation. Nucleic acid approaches are highly adaptable and could be tremendously beneficial for personalized strategies to combat AMR pathogens. Twit Text FOAVip Tackling Antimicrobial Resistance in the Shadow of COVID-19 ????mBio http://www.kidney.de/pget.php?&tw=1&pmid=34281392 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34281392 #FOAvip English Wikipedia <ref>{{Cite pmid|34281392}}</ref> Tackling Antimicrobial Resistance in the Shadow of COVID-19 #MMPMID34281392 Patel A mBio 2021[Aug]; 12 (4): e0047321 PMID34281392show ga The coronavirus disease 2019 (COVID-19) pandemic is a challenge for ongoing efforts to combat antimicrobial-resistant (AMR) bacterial infections. As we learn more about COVID-19 disease and drug stewardship evolves, there is likely to be a lasting impact of increased use of antimicrobial agents and antibiotics, as well as a lack of consistent access to health care across many populations. Sexually transmitted infections have been underreported during the pandemic and are often caused by some of the most drug-resistant pathogens. In their recent article in mBio, Parzych et al. (E. M. Parzych, S. Gulati, B. Zheng, M. A. Bah, et al., mBio 12:e00242-21, 2021, https://doi.org/10.1128/mBio.00242-21) focus on protection against Neisseria gonorrhoeae infection via in vivo delivery of an antigonococcal DNA-encoded antibody that has been modified for increased complement activation. Nucleic acid approaches are highly adaptable and could be tremendously beneficial for personalized strategies to combat AMR pathogens. |Anti-Bacterial Agents/*therapeutic use[MESH] |Antimicrobial Stewardship/*methods[MESH] |COVID-19/*pathology[MESH] |Coinfection/drug therapy/microbiology[MESH] |Drug Resistance, Multiple, Bacterial/*genetics[MESH] |Gonorrhea/drug therapy[MESH] |Health Services Accessibility[MESH] |Humans[MESH] |Microbial Sensitivity Tests[MESH] |Neisseria gonorrhoeae/drug effects/genetics[MESH] |Precision Medicine[MESH]Tackling Antimicrobial Resistance in the Shadow of COVID-19 (epmc).pdf DeepDyve Pubget Overpricing